DeepMed Research

KYOWA KIRIN CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public, Subsidiary

Established: 1949-07-01

Employees: 5.9K

Market Cap: -

Website: http://www.kyowa-kirin.co.jp

Clinical Trials

Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）

Phase 3

Recruiting

Conditions: Achondroplasia

Interventions: Drug: KK8398

First Posted Date: 2025-04-13

Last Posted Date: 2025-04-29

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT06926491

Locations: 🇯🇵
Aichi Children's Health and Medical Center, Ōbu, Aichi, Japan
🇯🇵
Osaka University Hospital, Suita, Osaka, Japan
🇯🇵
Osaka Women's and Children's Hospital, Waizumi, Osaka, Japan

and more 6 locations

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Phase 1

Recruiting

Conditions: Healthy Volunteers Essential Hypertension

Interventions: Drug: Placebo
Drug: KK3910

First Posted Date: 2025-02-12

Last Posted Date: 2025-05-04

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 144

Registration Number: NCT06823947

Locations: 🇯🇵
Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan

Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Drug: KK2845_2
Drug: KK2845_1
Drug: KK2845_3
Drug: KK2845_4

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-14

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT06812104

Locations: 🇯🇵
Hokkaido University Hospital, Sapporo, Hokkaido, Japan

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Phase 1

Recruiting

Conditions: X-linked Hypophosphatemia

Interventions: Drug: KK8123

First Posted Date: 2024-07-29

Last Posted Date: 2025-05-04

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT06525636

Locations: 🇺🇸
Yale Center for XLH/ Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
University of California - San Francisco, San Francisco, California, United States
🇺🇸
Indiana University School of Medicine University Hospital, Indianapolis, Indiana, United States

and more 5 locations

A Study of KK2269 in Adult Participants With Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Solid Tumor
Esophageal Adenocarcinoma
Advanced Solid Tumor
Gastroesophageal Junction Adenocarcinoma
Non Small Cell Lung Cancer
Gastric Adenocarcinoma

Interventions: Drug: KK2269
Drug: Docetaxel

First Posted Date: 2024-02-20

Last Posted Date: 2025-01-09

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 71

Registration Number: NCT06266299

Locations: 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇯🇵
Aichi Cancer Center, Nagoya city, Aichi, Japan

and more 3 locations

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: KK2260

First Posted Date: 2024-02-08

Last Posted Date: 2025-02-05

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 169

Registration Number: NCT06248411

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
Kobe University Hospital, Kobe, Hyogo, Japan
🇯🇵
Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan

and more 4 locations

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Phase 2

Recruiting

Conditions: Diabetic Macular Edema (DME)

Interventions: Drug: KHK4951
Drug: Aflibercept Injection

First Posted Date: 2023-11-03

Last Posted Date: 2025-04-29

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT06116916

Locations: 🇺🇸
Barnet Dulaney Perkins Eye Center - Phoenix, Mesa, Arizona, United States
🇺🇸
Retina Associates Southwest, P.C., Tucson, Arizona, United States
🇺🇸
Win Retina, Arcadia, California, United States

and more 171 locations

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Phase 2

Recruiting

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)

Interventions: Drug: KHK4951
Drug: Aflibercept Injection

First Posted Date: 2023-11-03

Last Posted Date: 2025-04-29

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT06116890

Locations: 🇺🇸
Barnet Dulaney Perkins Eye Center - Phoenix, Mesa, Arizona, United States
🇺🇸
Retina Associates Southwest, P.C., Tucson, Arizona, United States
🇺🇸
Win Retina, Arcadia, California, United States

and more 81 locations

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Phase 1

Recruiting

Conditions: Healthy Volunteers
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus (CLE)

Interventions: Drug: Placebo
Drug: KK4277

First Posted Date: 2022-06-08

Last Posted Date: 2023-08-08

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 116

Registration Number: NCT05411016

Locations: 🇯🇵
Fujita Health University Hospital, Kutsukake, Aichi, Japan
🇯🇵
Japan Community Health care Organization Chukyo Hospital, Minami, Aichi, Japan
🇯🇵
Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan

and more 20 locations

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Phase 4

Completed

Conditions: Tumor-Induced Osteomalacia (TIO)

Interventions: Drug: KRN23

First Posted Date: 2022-05-03

Last Posted Date: 2024-07-09

Lead Sponsor: Kyowa Kirin Co., Ltd.

Target Recruit Count: 9

Registration Number: NCT05357573

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, China
🇨🇳
Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy